When evaluated in RET fusion-positive preclinical models, lenvatinib effectively inhibits RET fusion kinases and RET pathway activity in vitro, and inhibits growth of RET fusion-positive tumor cells in vivo (212, 213). Here, RET is linked to neoplasm.